Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

NCT06706401 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

460

Enrollment

OTHER

Sponsor class

Conditions

Oropharynx Cancer
Larynx Cancer
Hypopharynx Cancer
Primary Head and Neck Tumor

Interventions

DRUG: Vesanoid
RADIATION: Standard radiotherapy
RADIATION: Tailored radiotherapy
DRUG: Cisplatin
DRUG: Cetuximab

Sponsor

Centre Leon Berard